Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

FDA Removes Clinical Hold on Solid Biosciences Experimental DMD Gene Therapy
Rare Daily Staff The U.S. Food and Drug Administration has lifted the clinical hold on Solid Biosciences’ phase 1/2 clinical trial for its… Continue Reading
Express Scripts Program Designed to Meet Needs of Payers, Not Patients
At the end of May, the pharmacy benefits manager Express Scripts announced a new program it said was aimed at “reducing the burden on… Continue Reading
New Bluebird Bio Data Shows Gene Therapy Promising for Thalessemia
Rare Daily Staff Bluebird Bio said data from its phase 1/2 Northstar study of its experimental LentiGlobin gene therapy in adolescents and… Continue Reading
Experimental Drug for “Elephant Man” Disease May Benefit Certain Cancers Too
Joseph Merrick, who was known as the Elephant Man, suffered from Proteus syndrome, a rare disorder that causes abnormal and disproportionate… Continue Reading
Rare Leader: James O’Brien, President of Prader-Willi Syndrome Australia
The Basics Name: James O’Brien Title/Organization: President, Prader-Willi Syndrome Australia; Founding Director, PWS Better Living… Continue Reading
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Developmental Disorders
Rare Daily Staff BridgeBio Pharma said it launched CoA Therapeutics, a biopharmaceutical company that will develop small-molecules designed… Continue Reading
Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders
Rare Daily Staff Inozyme Pharma has introduced a no-cost, third-party genetic testing program designed to improve detection and… Continue Reading

Follow us on Twitter